- For Print
- May 14, 2015
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results on Halaven® (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, “eribulin”) and Lenvima® (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, “lenvatinib”) will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
The main presentations for this year's ASCO meeting include an oral presentation highlighting the results of a Phase Ⅲ clinical study (Study 309) of eribulin in soft tissue sarcoma to be given on Monday, June 1. Furthermore, these findings have been chosen by ASCO to be featured in a press conference as part of the official press program starting at 10:30 a.m. (CDT) on Saturday, May 30.
For lenvatinib, an oral presentation on the results of a Phase Ⅱ clinical study (Study 205) of the agent in metastatic renal cell carcinoma will also be given on Monday, June 1.
In addition, the poster sessions include a presentation of the results of an analysis concerning biomarkers of response and resistance in the Phase Ⅲ study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT study).
Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.
Oral Presentations:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
Eribulin Abstract No: LBA10502 |
Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI) Oral Presentation | June 1 (Mon), 15:48-16:00 |
Lenvatinib Abstract No: 4506 |
Randomized phase 2 three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC) Oral Presentation | June 1 (Mon), 11:45-11:57 |
Major Poster Presentations:
*You can scroll to the left or right here
Lenvatinib Abstract No: 6013 |
Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy Poster Presentation | May 30 (Sat), 13:45-16:45 (Poster Discussion: 16:45-18:00) |
Lenvatinib Abstract No: 6014 |
Pharmacodynamic biomarkers of outcomes and resistance in the phase 3 study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT) Poster Presentation | May 30 (Sat), 13:45-16:45 (Poster Discussion: 16:45-18:00) |
Lenvatinib Abstract No: 6048 |
Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT Poster Presentation | May 30 (Sat), 13:45-16:45 |
- (Note)SELECT Study: Study of E7080 “LEnvatinib” in Differentiated Cancer of the Thyroid